Hartmut Kristeleit

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

J. Blake Bartlett, A Michael, Ian Clarke et al. · British Journal of Cancer · 2004 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

Peter Vink, Ignacio Delgado Mingorance, C. Maximiano Alonso et al. · Cancer · 2019 · 120 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

Peter Schmid, Catherine Harper‐Wynne, M. Ferreira et al. · JAMA Oncology · 2019 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 56 citations · Full text

Medicine, Oncology, Pharmacology +9